Rethinking Lentiviral Manufacturing for Cell and Gene Therapies: from Platform Design to Point-of-care Delivery

Lauren Coyle, Editor, BioInsights, speaks to Michael Kadan, Chief Operating Officer, Vector BioMed, and Boro Dropulić, Chief Executive Officer, Vector BioMed, on advances shaping lentiviral vector design and manufacturing. They discuss algorithm-driven vector engineering, targeted pseudotyping, and adaptable platforms that enhance transduction efficiency, scalability, and regulatory alignment. The interview highlights the growing momentum behind point-of-care manufacturing to reduce turnaround and expand access to autologous therapies. It emphasizes the need for streamlined phase-appropriate development and cost-efficient, platform-based solutions to sustain investment and growth across the cell and gene therapy sector.

Complete the Form to Access Interview PDF